Background. The vascular endothelium serves as a key organ in regulating hemostasis, vasodilation, and anticoagulant balance. Endothelial dysfunction (ED) plays a central role in the pathogenesis of atherosclerosis, thrombosis, inflammatory diseases, and COVID-19 complications, manifesting as reduced NO-dependent vasodilation, activation of coagulation, and loss of the antithrombogenic properties of the vascular intima. Assessment of endothelial function holds significant clinical potential for diagnosis, prognosis, and therapy monitoring; however, existing methods are limited in terms of specificity, reproducibility, and interpretation. Objective. To systematize current data on the advantages and disadvantages of methods for assessing endothelial function, including biomarkers, functional tests, and coagulological approaches. Materials and methods. A systematic literature search was performed in PubMed, PMC, ResearchGate, Scopus, and Web of Science databases for the period from 2000 to 2026. Keywords included “endothelial dysfunction assessment”, “hemostasis biomarkers”, and others. Reviews, meta-analyses, and original studies in English and Russian were included; abstracts and case reports without statistical data were excluded. Results. Biomarkers (vWF, sPECAM-1, sP-selectin, VEGF, PGI2, endocan, syndecans) reflect endothelial activation and damage but lack specificity in the context of inflammation. Functional tests (FMD, viscometry) evaluate vasoreactivity and rheology but require rigorous standardization. Coagulological methods (platelet aggregation, protein C activity) provide indirect indicators of dysfunction. Promising approaches include flow cytometry (CECs, EVs) and microfluidic chambers for cellular analysis. Conclusion. A combination of methods is preferable for comprehensive assessment; future prospects lie in standardized protocols for predicting thrombotic risks and guiding therapy.